$ACTU News

Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanced Cancer Patients, With Focus On Metastatic Melanoma, NSCLC, Colorectal, And Pancreatic Cancers With Initiation Planned For 2H 2026

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

Actuate Therapeutics shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $15 price target.

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Actuate Announces Publication In Nature Medicine Reporting Phase 2 Data Showing Elraglusib + Chemotherapy Improves Survival By >40% In Metastatic Pancreatic Cancer Trial

HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $15

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors

Actuate Therapeutics to Present at The Citizens Life Sciences Conference

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage Form Of Elraglusib In Patients With Advanced Cancer

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026